November 2024

48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to support

BEIJING, Nov. 19, 2024 /PRNewswire/ — Baijiayun Group Ltd (“Baijiayun” or the “Company”) (NASDAQ: RTC), a one-stop AI video solution provider, recently made contributions to the ” Urban and Rural School Community ” project. On November 11th, the training wor

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: